Generate:Biomedicines

In an area that has been called the most innovative square mile on the planet, being named a 2024 BostInno Fire Award honoree is no small feat. Recognized in the Late Stage Biotech category — defined as biotechnology companies in or approaching trial phases — #TeamGenerate is proud to stand among the leaders driving breakthroughs in this innovation ecosystem. Thank you, Boston Business Journal, for recognizing our work to program biology and create transformative therapeutics. Are you #RelentlesslyCurious? #UnapologeticallyScientific? If yes, join us: https://lnkd.in/gKaKkEGJ #ProgrammingBiology | #GenerativeAI

#RelentlessCuriosity drives us. #AudaciousAmbition fuels us. Last weekend, #TeamGenerate came together with the Somerville Homeless Coalition for their 29th Annual 5K Road Race, supporting their mission to provide housing and essential services to those in need. Who we are is about more than just breakthrough science—it is about being connected to the communities where we live and work. Led by Atreyi Bhattacharya and Sarah Cowles, we were proud to have the largest team at this year’s race. Driven by purpose? Join us: https://lnkd.in/gKaKkEGJ #FiercelyUnited | #Community

We applaud David Baker (University of Washington), Demis Hassabis, and John Jumper (Google DeepMind) on receiving the 2024 The Nobel Prize in Chemistry for their pioneering work in computational #proteindesign and protein structure prediction. This recognition underscores how computational approaches are rapidly advancing biology and opening new frontiers in science. As we continue to push the boundaries of what’s possible, their contributions strengthen the entire field’s momentum toward a new era of discovery. #ProgrammingBiology | #GenerativeAI

#Oktoberfest was the perfect way to kick off the month—celebrating teamwork, fun, and a little friendly competition. Lederhosen and a stein holding contest brought out the best of #TeamGenerate. A big congrats to Chase Duffin, this year’s stein holding champion! This tradition is one we look forward to every year. Check out the highlights below. #FiercelyUnited | #AudaciouslyAmbitious

On October 16, Andrew Dunn of Endpoints News will moderate the panel “Insurgents vs. Incumbents — Approaches to AI at Tiny Startups and Big Pharmas” at Endpoints AI Day 2024. Our EVP of Research & Development, Alexandra Snyder, MD, will join Jakob Uszkoreit of Inceptive and Sean Bruich (he/him) of Amgen to explore how #AI is reshaping biopharma—from drug discovery to Phase III—and whether the future belongs to legacy drugmakers or new tech-driven startups. The future of AI in pharma is here. Don’t miss out. Learn more:?https://lnkd.in/gF48qYZ9 #ProgrammingBiology | #GenerativeAI

On the Vanguards of Healthcare by Bloomberg Intelligence podcast, Gevorg Grigoryan, our Co-Founder and CTO, and Alexandra Snyder, MD, our Head of Research & Development, joined Andrew Galler of Morgan Stanley and Sam Fazeli of Bloomberg to explore how #AI is changing the future of drug development. Gevorg shared, “What excites me most is that we’re at a point where we can essentially tackle any molecular task. We can generate exactly what we need to solve problems that were previously unsolvable.” Curious how AI is driving breakthroughs in drug development? Listen to the podcast here: https://lnkd.in/e5d5e5M5 #GenerativeAI | #ProgrammingBiology

Today, we’ve hit another exciting milestone—30,000 followers. This is a testament to the growing impact of #GenerativeAI in biology and the future of scientific discovery. Thank you for being part of this journey, guided by our relentless curiosity, audacious ambition, and drive to push the boundaries of what’s possible. #AI | #ML | #ProgrammingBiology

What does it take to transition from academia to industry in the fields of #AI and #GenerativeBiology?? ? Tomorrow at 1:00pm ET, Tharindi Hapuarachchi, PhD will share her perspective and insights at the Harvard Medical School & GSAS Harvard Biotech Club’s annual career fair and expert panel.?? ? Tharindi will be joined by panelists Christalyn Rhodes, Ph.D. of Eli Lilly and Company and Claire Leurent PhD MBA of AbbVie Ventures, with moderation by Pearl Freier of Cambridge BioPartners, Inc. ? Check out the details here: https://lnkd.in/ddwKGrWR ? ? #TeamGenerate | #ProgrammingBiology?

Next week at Fierce Biotech Summit 2024, our Chief Corporate Affairs Officer, Kym White, and our Senior Vice President of Business Development & Strategy, Sahm Nasseri, will share their insights in two key sessions. On Monday at 4:00pm?ET, Kym will join Robert Zirkelbach of PhRMA, Kate Beresford O'Malley of Moderna, and Natacha Gassenbach of Biogen on the panel, "The Strategic Powerhouse Within: The Case to Bring Communications Teams to the Table,” to explore how communications teams shape business strategies across drug pricing, M&A, and clinical trials. On Tuesday at 11:30am. ET, Sahm will be part of "Lessons Learned From a Billion Dollar Deal,” alongside Polly Brown of AstraZeneca discussing the strategies and key decisions that drove the success of recent high-profile deals. Get the full details here: https://lnkd.in/gtM6CwrF #RelentlesslyCurious | #AudaciouslyAmbitious

How do you turn #AI conversations into concrete progress? Next week, Tharindi Hapuarachchi, PhD will represent #TeamGenerate at #Benchtalk 2024, joining Will Weiss of Eli Lilly and Company and Ron Hause of Shape Therapeutics Inc. They’ll dive into the toughest challenges in R&D—like overcoming data quality issues—and share how to get your data AI-ready and integrated into your workflows. This is where AI meets real-world application. Don’t miss it. Get the details here: https://lnkd.in/e-j2YKUb #GenerativeAI | #ProgrammingBiology